New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders -- complex conditions with severe energy deficiency for which no proven effective treatments exist. Future clinical research is needed to explore whether the drug, cysteamine bitartrate, will meaningfully benefit patients.
from Top Health News -- ScienceDaily https://ift.tt/2Ua8jKo
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
New research links walnut consumption as a contributing factor that could suppress growth and survival of breast cancers. from Top Health ...
-
Researchers report on chimpanzees in Guinea fishing and consuming freshwater crabs, something previously undiscovered. The article describes...
-
The IT major further said the Ebit margin for the current quarter is expected to be between 20.5-21 per cent from Home Page https://ift.tt...
No comments:
Post a Comment